- NCIt
- C7480
Loading cancer entity…
Loading cancer entity…
Clinical trials
744 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (121)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01536054 | Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Phase 1 | 7 | Roswell Park Cancer InstituteOTHER | 1 | Mar 27, 2020 | clinicaltrials |
| NCT00692900 | Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer | completed | Phase 1 | 25 | University of PittsburghOTHER | 1 | Mar 12, 2020 |
| NCT02199171 | Heated Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Peritoneal Cancer | completed | Phase 1 | 30 | University of California, IrvineOTHER | 1 | Jan 31, 2020 | clinicaltrials |
| NCT01237067 | Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers | completed | Phase 1 | 77 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT02661815 | A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer | terminated | Phase 1 | 6 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT00478452 | Dendritic Cell Vaccine for High Risk Ovarian Cancer Patients(DC-Ova) | completed | Phase 1 | 14 | University of PennsylvaniaOTHER | 1 | Oct 23, 2019 | clinicaltrials |
| NCT01663857 | A Study LY2228820 for Recurrent Ovarian Cancer | completed | Phase 1 / Phase 2 | 118 | Eli Lilly and CompanyINDUSTRY | 4 | Sep 11, 2019 | clinicaltrials |
| NCT02012192 | GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer | terminated | Phase 1 / Phase 2 | 133 | Medical University InnsbruckOTHER | 4 | Aug 13, 2019 | clinicaltrials |
| NCT01074411 | Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 1 | 33 | National Cancer Institute (NCI)NIH | 1 | Aug 9, 2019 | clinicaltrials |
| NCT04029909 | A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer | unknown | Phase 1 | 12 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | Jul 23, 2019 | clinicaltrials |
| NCT00079430 | Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | 113 | National Cancer Institute (NCI)NIH | 2 | Jul 22, 2019 | clinicaltrials |
| NCT01459380 | Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 1 | Jul 22, 2019 | clinicaltrials |
| NCT01281514 | A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer | completed | Phase 1 | 21 | Fox Chase Cancer CenterOTHER | 1 | Jul 11, 2019 | clinicaltrials |
| NCT00357448 | Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer | completed | Phase 1 | 11 | University of WashingtonOTHER | 1 | May 14, 2019 | clinicaltrials |
| NCT01489371 | EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 1 | 16 | Gynecologic Oncology GroupNETWORK | 1 | Mar 12, 2019 | clinicaltrials |
| NCT00436501 | VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | completed | Phase 1 / Phase 2 | 58 | National Cancer Institute (NCI)NIH | 1 | Feb 26, 2019 | clinicaltrials |
| NCT02050009 | Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | withdrawn | Phase 1 | 0 | Fox Chase Cancer CenterOTHER | 1 | Feb 20, 2019 | clinicaltrials |
| NCT01083537 | Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction | terminated | Phase 1 / Phase 2 | 1 | University Health Network, TorontoOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT00002600 | Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer | completed | Phase 1 | 23 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 6, 2019 | clinicaltrials |
| NCT02433626 | Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies(COTI2-101) | unknown | Phase 1 | 51 | Critical Outcome Technologies Inc.INDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
| NCT02046421 | Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 | 31 | University of ChicagoOTHER | 1 | Sep 11, 2018 | clinicaltrials |
| NCT00910000 | Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer | terminated | Phase 1 / Phase 2 | 15 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 10, 2018 | clinicaltrials |
| NCT00268918 | Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients | completed | Phase 1 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 27, 2018 | clinicaltrials |
| NCT03283943 | PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers. | unknown | Phase 1 | 22 | British Columbia Cancer AgencyOTHER | 1 | Jul 11, 2018 | clinicaltrials |
| NCT00892736 | Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy | completed | Phase 1 | 98 | National Cancer Institute (NCI)NIH | 1 | Jun 29, 2018 | clinicaltrials |
| NCT02833506 | Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | withdrawn | Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 1 | May 1, 2018 | clinicaltrials |
| NCT02275039 | p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer | completed | Phase 1 | 12 | City of Hope Medical CenterOTHER | 1 | Apr 30, 2018 | clinicaltrials |
| NCT02534922 | Study of Prolanta™ in Recurrent or Persistent Epithelial Ovarian Cancer(ProlantaOC) | unknown | Phase 1 | 18 | Oncolix, Inc.INDUSTRY | 1 | Feb 14, 2018 | clinicaltrials |
| NCT01219777 | Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian | completed | Phase 1 | 9 | Ritu SalaniOTHER | 1 | Feb 8, 2018 | clinicaltrials |
| NCT01188876 | Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 50 | Massachusetts General HospitalOTHER | 1 | Jan 19, 2018 | clinicaltrials |
| NCT00303888 | Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer | terminated | Phase 1 | 31 | Yale UniversityOTHER | 1 | Jan 17, 2018 | clinicaltrials |
| NCT00903630 | Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | terminated | Phase 1 / Phase 2 | 15 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT01145430 | Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Dec 22, 2017 | clinicaltrials |
| NCT02118285 | Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | completed | Phase 1 | 2 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT00287859 | Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | terminated | Phase 1 | 5 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00287885 | Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer | completed | Phase 1 | 18 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Nov 29, 2017 | clinicaltrials |
| NCT00526617 | A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients | completed | Phase 1 | 41 | AbbVieINDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT01264432 | Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 2 | Nov 21, 2017 | clinicaltrials |
| NCT01416038 | Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer | completed | Phase 1 | 19 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 2 | Apr 21, 2017 | clinicaltrials |
| NCT02262455 | Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors | completed | Phase 1 | 32 | Santa Maria BiotherapeuticsINDUSTRY | 1 | Feb 13, 2017 | clinicaltrials |
| NCT01308944 | Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients | completed | Phase 1 | 24 | Washington University School of MedicineOTHER | 1 | Jan 12, 2017 | clinicaltrials |
| NCT00637390 | A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer. | terminated | Phase 1 | 3 | University of Michigan Rogel Cancer CenterOTHER | 1 | Dec 2, 2016 | clinicaltrials |
| NCT00602277 | Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy | completed | Phase 1 | 70 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2016 | clinicaltrials |
| NCT02627430 | Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 26, 2016 | clinicaltrials |
| NCT00091377 | Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 65 | MEI Pharma, Inc.INDUSTRY | 2 | Jul 14, 2016 | clinicaltrials |
| NCT00045175 | UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer | completed | Phase 1 | 33 | University Health Network, TorontoOTHER | 1 | Jun 23, 2016 | clinicaltrials |
| NCT00182767 | Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer | completed | Phase 1 / Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Mar 10, 2016 | clinicaltrials |
| NCT01709487 | Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy | completed | Phase 1 / Phase 2 | 19 | Jules Bordet InstituteOTHER | 1 | Feb 24, 2016 | clinicaltrials |
| NCT02470559 | Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent | withdrawn | Phase 1 | 0 | Barbara Ann Karmanos Cancer InstituteOTHER | 0 | Feb 17, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Mar 27, 2020source: clinicaltrials